Research
Glycolipid-lectin driven endocytosis as a therapeutic vulnerability in breast cancer
Nature ·
The Brief
- A study identifies glycolipid-lectin driven endocytosis as a therapeutic vulnerability in breast cancer.
- Only the title and feed listing were available; no summary or methodological details were provided.
Why it matters
It points to a possible therapeutic target in breast cancer based on glycolipid-lectin endocytosis; the sources do not state clinical relevance.
Who’s affected
- cancer researchers
- breast cancer drug developers
- #breast cancer
- #endocytosis
- #glycolipids
- #lectins
- #cancer biology